200 related articles for article (PubMed ID: 26269002)
21. Risk of stroke with thiazolidinediones: a ten-year nationwide population-based cohort study.
Lu CJ; Sun Y; Muo CH; Chen RC; Chen PC; Hsu CY
Cerebrovasc Dis; 2013; 36(2):145-51. PubMed ID: 24029780
[TBL] [Abstract][Full Text] [Related]
22. Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis.
Rajagopalan R; Rosenson RS; Fernandes AW; Khan M; Murray FT
Clin Ther; 2004 Sep; 26(9):1400-10. PubMed ID: 15531002
[TBL] [Abstract][Full Text] [Related]
23. Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance.
Durbin RJ
Diabetes Obes Metab; 2004 Jul; 6(4):280-5. PubMed ID: 15171752
[TBL] [Abstract][Full Text] [Related]
24. The peroxisome proliferator-activated receptor-gamma agonist pioglitazone increases number and function of endothelial progenitor cells in patients with coronary artery disease and normal glucose tolerance.
Werner C; Kamani CH; Gensch C; Böhm M; Laufs U
Diabetes; 2007 Oct; 56(10):2609-15. PubMed ID: 17623816
[TBL] [Abstract][Full Text] [Related]
25. Targeting Pioglitazone Hydrochloride Therapy After Stroke or Transient Ischemic Attack According to Pretreatment Risk for Stroke or Myocardial Infarction.
Kernan WN; Viscoli CM; Dearborn JL; Kent DM; Conwit R; Fayad P; Furie KL; Gorman M; Guarino PD; Inzucchi SE; Stuart A; Young LH;
JAMA Neurol; 2017 Nov; 74(11):1319-1327. PubMed ID: 28975241
[TBL] [Abstract][Full Text] [Related]
26. Successful treatment of prediabetes in clinical practice using physiological assessment (STOP DIABETES).
Armato JP; DeFronzo RA; Abdul-Ghani M; Ruby RJ
Lancet Diabetes Endocrinol; 2018 Oct; 6(10):781-789. PubMed ID: 30224284
[TBL] [Abstract][Full Text] [Related]
27. Impaired glucose tolerance increases stroke risk in nondiabetic patients with transient ischemic attack or minor ischemic stroke.
Vermeer SE; Sandee W; Algra A; Koudstaal PJ; Kappelle LJ; Dippel DW;
Stroke; 2006 Jun; 37(6):1413-7. PubMed ID: 16627787
[TBL] [Abstract][Full Text] [Related]
28. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study.
Erdmann E; Dormandy JA; Charbonnel B; Massi-Benedetti M; Moules IK; Skene AM;
J Am Coll Cardiol; 2007 May; 49(17):1772-80. PubMed ID: 17466227
[TBL] [Abstract][Full Text] [Related]
29. Rationale, Design, and Baseline Characteristics of Beijing Prediabetes Reversion Program: A Randomized Controlled Clinical Trial to Evaluate the Efficacy of Lifestyle Intervention and/or Pioglitazone in Reversion to Normal Glucose Tolerance in Prediabetes.
Luo Y; Paul SK; Zhou X; Chang C; Chen W; Guo X; Yang J; Ji L; Wang H
J Diabetes Res; 2017; 2017():7602408. PubMed ID: 28168204
[No Abstract] [Full Text] [Related]
30. Pioglitazone for primary stroke prevention in Asian patients with type 2 diabetes and cardiovascular risk factors: a retrospective study.
Hung YC; Chiu LT; Huang HY; Bau DT
Cardiovasc Diabetol; 2020 Jun; 19(1):94. PubMed ID: 32563247
[TBL] [Abstract][Full Text] [Related]
31. Pioglitazone is equally effective for diabetes prevention in older versus younger adults with impaired glucose tolerance.
Espinoza SE; Wang CP; Tripathy D; Clement SC; Schwenke DC; Banerji MA; Bray GA; Buchanan TA; Henry RR; Kitabchi AE; Mudaliar S; Stentz FB; Reaven PD; DeFronzo RA; Musi N
Age (Dordr); 2016 Dec; 38(5-6):485-493. PubMed ID: 27585671
[TBL] [Abstract][Full Text] [Related]
32. Prediabetes in patients with stroke or transient ischemic attack: prevalence, risk and clinical management.
Fonville S; Zandbergen AA; Koudstaal PJ; den Hertog HM
Cerebrovasc Dis; 2014; 37(6):393-400. PubMed ID: 24993381
[TBL] [Abstract][Full Text] [Related]
33. Detection of undiagnosed diabetes and prediabetic states in high-risk emergency department patients.
Charfen MA; Ipp E; Kaji AH; Saleh T; Qazi MF; Lewis RJ
Acad Emerg Med; 2009 May; 16(5):394-402. PubMed ID: 19302369
[TBL] [Abstract][Full Text] [Related]
34. Predictors of recurrent events in patients with cryptogenic stroke and patent foramen ovale within the CLOSURE I (Evaluation of the STARFlex Septal Closure System in Patients With a Stroke and/or Transient Ischemic Attack Due to Presumed Paradoxical Embolism Through a Patent Foramen Ovale) trial.
Elmariah S; Furlan AJ; Reisman M; Burke D; Vardi M; Wimmer NJ; Ling S; Chen X; Kent DM; Massaro J; Mauri L;
JACC Cardiovasc Interv; 2014 Aug; 7(8):913-20. PubMed ID: 25147037
[TBL] [Abstract][Full Text] [Related]
35. Pioglitazone for secondary prevention after ischemic stroke and transient ischemic attack: rationale and design of the Insulin Resistance Intervention after Stroke Trial.
Viscoli CM; Brass LM; Carolei A; Conwit R; Ford GA; Furie KL; Gorman M; Guarino PD; Inzucchi SE; Lovejoy AM; Parsons MW; Peduzzi PN; Ringleb PA; Schwartz GG; Spence JD; Tanne D; Young LH; Kernan WN;
Am Heart J; 2014 Dec; 168(6):823-9.e6. PubMed ID: 25458644
[TBL] [Abstract][Full Text] [Related]
36. Effect of pioglitazone on body composition and bone density in subjects with prediabetes in the ACT NOW trial.
Bray GA; Smith SR; Banerji MA; Tripathy D; Clement SC; Buchanan TA; Henry RR; Kitabchi AE; Mudaliar S; Musi N; Ratner RE; Schwenke DC; Stentz FB; Reaven PD; DeFronzo RA
Diabetes Obes Metab; 2013 Oct; 15(10):931-7. PubMed ID: 23551856
[TBL] [Abstract][Full Text] [Related]
37. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study.
Kendall DM; Rubin CJ; Mohideen P; Ledeine JM; Belder R; Gross J; Norwood P; O'Mahony M; Sall K; Sloan G; Roberts A; Fiedorek FT; DeFronzo RA
Diabetes Care; 2006 May; 29(5):1016-23. PubMed ID: 16644631
[TBL] [Abstract][Full Text] [Related]
38. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10).
Wilcox R; Kupfer S; Erdmann E;
Am Heart J; 2008 Apr; 155(4):712-7. PubMed ID: 18371481
[TBL] [Abstract][Full Text] [Related]
39. [Effects of thiazolidinediones on dyslipidemia in patients with type 2 diabetes. Are all equally vasoprotective?].
Haberbosch W
Herz; 2007 Feb; 32(1):51-7. PubMed ID: 17323035
[TBL] [Abstract][Full Text] [Related]
40. Effects of pioglitazone on the incidence of dementia in patients with diabetes.
Chou PS; Ho BL; Yang YH
J Diabetes Complications; 2017 Jun; 31(6):1053-1057. PubMed ID: 28254448
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
